The Role of Breast Cancer Derived Prostaglandin E2 in the Elaboration of a Therapeutic Immune Response
Final rept. 1 Jul 1998-30 Jun 2001
PENNSYLVANIA UNIV PHILADELPHIA
Pagination or Media Count:
The principal goal was to understand why breast cancer cells are able to evade the host immune system despite the presence of tumor antigens and tumor antigen-specific T lymphocytes. We had previously demonstrated that tumor-derived prostaglandin E2 PGE2 directly contributes to the lack of a significant immune response to breast cancer cells. However, the production of PGE2 by breast cancer cells did not completely explain the immune suppressive effect of breast cancer cells. We have subsequently demonstrated that GA733-2mEGP, a type I cell surface breast cancer protein, is able to efficiently block the presentation of a variety of antigens from dendritic cells DC.
- Medicine and Medical Research